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Abstract
Background: Plasmodium vivax is the most geographically widespread species among human malaria parasites.
Immunopathological studies have shown that platelets are an important component of the host innate immune
response against malaria infections. The objectives of this study were to quantify thrombocytopaenia in P. vivax
malaria patients and to determine the associated risks of severe thrombocytopaenia in patients with vivax malaria
compared to patients with P. falciparum malaria.
Main body: A systematic review and meta-analysis of the available literature on thrombocytopaenia in P. vivax
malaria patients was undertaken. Relevant studies in health-related electronic databases were identified and
reviewed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed.
Fifty-eight observational studies (n = 29 664) were included in the current review. Severe thrombocytopaenia
(< 50 000/mm3) to very severe thrombocytopaenia (< 20 000/mm3) was observed in 10.1% of patients with
P. vivax infection. A meta-analysis of 11 observational studies showed an equal risk of developing severe/very
severe thrombocytopaenia between the patients with P. vivax malaria and those with P. falciparum malaria
(OR: 1.98, 95% CI: 0.92–4.25). This indicates that thrombocytopaenia is as equally a common manifestation in
P. vivax and P. falciparum malaria patients. One study showed a higher risk of developing very severe
thrombocytopaenia in children with severe P. vivax malaria than with severe P. falciparum malaria (OR: 2.80,
95% CI: 1.48–5.29). However, a pooled analysis of two studies showed an equal risk among adult severe cases
(OR: 1.19, 95% CI: 0.51–2.77). This indicates that the risk of developing thrombocytopaenia in P. vivax malaria
can vary with immune status in both children and adults. One study reported higher levels of urea and
serum bilirubin in patients with P. vivax malaria and severe thrombocytopaenia compared with patients mild
thrombocytopaenia or no thrombocytopaenia, (P < 0.001 in all comparisons). A pooled analysis of two other
studies showed a similar proportion of bleeding episodes with thrombocytopaenia in severe P. vivax patients
and severe P. falciparum patients (P = 0.09). This implied that both P. vivax and P. falciparum infections could
present with bleeding episodes, if there had been a change in platelet counts in the infected patients. A pooled analysis
of another two studies showed an equal risk of mortality with severe thrombocytopaenia in both P. vivax and P. falciparum
malaria patients (OR: 1.16, 95% CI: 0.30–4.60). However, due to the low number of studies with small sample sizes within the
subset of studies that provided clinically relevant information, our confidence in the estimates is limited.
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Conclusion: The current review has provided some evidence of the clinical relevance of severe thrombocytopaenia in P.
vivax malaria. To substantiate these findings, there is a need for well designed, large-scale, prospective studies among
patients infected with P. vivax. These should include patients from different countries and epidemiological settings with
various age and gender groups represented.
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Background
Plasmodium vivax is the most geographically widespread
species of human malaria parasites, affecting almost 40%
of the world’s population [1–3]. The invisibility of the
dormant liver stages of P. vivax to any diagnostic
method may lead to an underestimation of the true
prevalence of P. vivax far more than P. falciparum. This
means P. vivax parasites could be highly prevalent in
many endemic settings [3]. Most recorded P. vivax mal-
aria cases originate from South East Asia and the Western
Pacific, and a significant number also occur in Africa and
South America [1–4]. Immunopathological studies have
shown that platelets are an important component of the
host innate immune responses against malaria infection
[5, 6]. Thrombocytopaenia (platelet count < 150 000/mm3)
appears to be a very frequent haematological alteration in
acute malaria infections [2, 5–7]. Severe malaria is defined
by a demonstration of asexual forms of the malaria para-
sites in the blood of a patient with a potentially fatal mani-
festation or complication of malaria in whom other
diagnoses have been excluded [4, 8]. In brief, the clinical
features of severe falciparum malaria are impaired con-
sciousness, prostration, multiple convulsions, acute re-
spiratory distress, circulatory collapse or shock, acute
kidney injury, clinical jaundice and abnormal bleeding [8].
Although thrombocytopaenia is not included in the
current World Health Organization (WHO) criteria for
defining severe P. falciparum malaria [8], its clinical im-
portance has been widely recognized. For instance, a
retrospective analysis on 614 patients has shown that
multi-organ dysfunction (MOD) and subsequent risk of
death were found in patients with thrombocytopaenia [9].
However similar information on P. vivax malaria is limited.
Since the life cycle and pathophysiology of P. falciparum
and P. vivax infections are different, it is important to
understand the role of platelets in P. vivax malaria.
There has been a recent increase in studies in the litera-
ture which have assessed the frequency of thrombocyto-
paenia in P. vivax infection. These studies varied with
respect to geographical location, thrombocytopaenia
grading, study design and other variables. Understanding
the occurrence and role of thrombocytopaenia in P. vivax
malaria may improve clinical practice guidelines. The aim
of this study was to undertake a critical analysis of the
available literature on thrombocytopaenia in P. vivax mal-
aria. The overall objectives of this study were to quantify
thrombocytopaenia in P. vivax malaria patients and to
establish the associated relative risks of severe thrombo-
cytopaenia in patients with P. vivax malaria compared to
patients with P. falciparum malaria.
Methods
The current review was done, following the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guideline [10] (Additional file 2).
Literature search
One investigator searched for the original studies, ad-
dressing thrombocytopaenia in human P. vivax malaria.
A literature search in electronic database of MEDLINE
(1946 to October 2017), EMBASE (1947 to October
2017), Google Scholar, the Latin American and Caribbean
Health Sciences Literature (LILACS) and African Journals
Online (AJOL). The following Medical Subject Heading
(MeSH) terms were used: “(vivax malaria OR vivax OR
Plasmodium vivax OR falciparum malaria OR falciparum
OR Plasmodium falciparum)” combined with “(platelets
OR platelet counts OR thrombocytopaenia OR
thrombocytopenia).” The search strategy was slightly
adjusted according to the requirements of different data-
bases. The search was limited to studies published in
English until October 2017. We also checked the refer-
ences of retrieved articles and relevant reviews for any
additional studies.
Studies were selected if they (i) had ≥10 participants in-
fected with P. vivax, residing in malaria endemic countries;
(ii) were observational studies, (iii) provided data on fre-
quency of thrombocytopaenia in P. vivax infection, com-
pared frequency/risk of thrombocytopaenia between P.
vivax and P. falciparum infection or between severe vivax
malaria and uncomplicated vivax malaria/healthy controls,
and (iv) provided relative risk (RR) or odds ratio (OR) esti-
mates with its 95% confidence interval (CI) (or raw data to
compute the estimates) of the association between P. vivax
and P. falciparum or between severe vivax malaria and
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uncomplicated vivax malaria/healthy controls. If more
than one study presented data from the same participants,
the study with more complete information was used.
Studies not meeting the above criteria were excluded.
Studies assessing a special group of the population such as
imported malaria or pregnant women were also excluded.
This is because acquisition of immunity to malaria in
people with imported malaria is different from those
residing in endemic countries. Also, physiological changes
in pregnant women are different from non-pregnant
population.
Thrombocytopaenia was further classified into mild
(100–150 000/mm3), moderate (50–100 000/mm3) [11],
severe (< 50 000/mm3) and very severe thrombocyto-
paenia (< 20 000/mm3) [12]. The platelet count or grad-
ing used in the analysis was as reported by the authors
in their published work. Parasitological diagnosis of mal-
aria was made based on microscopy of Giemsa-stained
thick/thin blood films (TBF), rapid onsite diagnostic test
(RDT) or any diagnostic technique (e.g. QBC), regardless
of subsequent PCR-based confirmation of the species. Se-
vere/complicated P. vivax malaria and uncomplicated/non-
severe P. vivax malaria in the current analysis were as de-
scribed by the authors in the primary studies [12, 46]. The
current review considered only patients with mono-
infections, so patients with mixed infections were excluded.
Data extraction and data synthesis
Two investigators individually screened the titles and ab-
stracts, and then selected full-text articles, according to the
inclusion criteria. The two investigators independently ex-
tracted information from each included study using a data
extraction form prepared for this meta-analysis. This data
extraction form had been pre-tested by the investigators on
a sample of papers to check its utility, comprehensiveness
and ease of use. Information collected was author, year of
publication, country, patient characteristics (e.g. mean age,
gender), study characteristics (e.g. sample size, study
design, settings) and the reported clinical outcomes.
Disagreements between the two investigators were resolved
by consensus.
To assess the pooled proportions of thrombocyto-
paenia in P. vivax malaria, proportion data was extracted
from the included studies. Raw cell counts were ex-
tracted from the studies and Freeman-Tukey double arc-
sine transformation and exact CI were employed with
the individual studies for that purpose. Meta-analysis of
observational studies, which assessed the risk associated
with severe thrombocytopaenia in P. vivax malaria, was
performed. The odds ratio (OR) of the pooled analysis was
used to compare dichotomous data [13]. For the studies
with mean and standard deviation (SD) of platelet counts,
the mean difference (MD) and its 95% CI for the pooled
analysis were used. When an individual study provided
mean value and range, the range was transformed to SD
through the formula SD = ((maximum-minimum)/4). If
the studies provided median and interquartile ranges, the
data was transformed into mean and SD, using a formula
developed by Hozo and associates [14]. The I2 test was
used for the assessment of statistical heterogeneity be-
tween studies. A value of I2 > 50% indicated substantial
heterogeneity [15]. The random effects model was
employed as there was substantial heterogeneity between
studies. Data analysis was done by STATA 14.0
(STATACorp, Txt, USA).
Results
Figure 1 provides a four-phase flow chart of the study
selection process. The initial search yielded 1025 cita-
tions. After the title and abstract screening, 77 full-text
papers were reviewed and a final selection of 58 studies
(a total of 5536 patients had thrombocytopaenia
amongst a total of 29 664 patients investigated) met the
pre-specified inclusion criteria [11, 12, 16–71]. A
summary of the 19 excluded studies [7, 72–89] is
provided in Additional file 3.
Characteristics of the included studies
All studies included in the present analysis used observa-
tional designs. Twenty-nine studies (50% of the included
58 studies) were prospective studies. Of them, the vast ma-
jority of participants infected with P. vivax (66%, 19 552/
29664) were from a single large study conducted in
Indonesia [11]. Half of the studies were conducted in India
Fig. 1 PRISMA flow chart showing the study selection process
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(50%) and the study period covered the years 1988–2015.
Only 25% of the included studies had PCR confirmation of
parasite species (Additional file 4).
Overall, a pooled analysis showed that 18.7% (5536/
29 664, 95% CI: 17.0–20.2%) of patients with P. vivax mal-
aria had platelet counts < 150 000/mm3. Of these, 10.1%
(2674/23 412, 95% CI: 9.0–10.8%) of the patients infected
with P. vivax had either severe thrombocytopaenia (9%)
or very severe thrombocytopaenia (13%) (Fig. 2). The pro-
portions of mild and moderate thrombocytopaenia are
presented in Additional file 5. There was an absence of
statistical heterogeneity (I2: 0%), suggesting a high level of
homogeneity between studies in each gradient of
thrombocytopaenia.
A subgroup analysis of 11 studies (11,12,20,22,30,33,
38,55,66,69,70) showed patients with P. vivax malaria
(1930/ 20 863) and those with P. falciparum malaria
(5895/ 38 450) had an equal risk of developing severe/very
severe thrombocytopaenia, (OR: 1.98, 95% CI: 0.92–4.25)
(Table 1). In a subgroup of 3 studies, a pooled analysis
showed patients with severe P. vivax malaria and those
with severe P. falciparum malaria had an equal risk of de-
veloping severe/very severe thrombocytopaenia [12, 20,
38]. Further stratification by age groups showed children
with severe P. vivax malaria (60/278) had a higher risk of
developing very severe thrombocytopaenia than in those
with severe P. falciparum malaria (13/145) (OR: 2.80, 95%
CI: 1.48–5.29) [12]. However an equal risk was observed
for adult severe cases with P. vivax malaria and those with
P. falciparum malaria (45/186 vs 70/207, OR: 1.19, 95%
CI: 0.51–2.77, P = 0.22) [20, 38] (Fig. 3).
A subset of 4 studies [24, 35, 41, 58] reported the
mean platelet counts. Decreased platelet counts were
recorded in patients with P. vivax malaria compared
to the healthy controls (P < 0.001 in all four studies)
(Additional file 6). In another subgroup of 2 studies with
PCR confirmed malaria [12, 29], the mean platelet counts
were almost the same in both uncomplicated P. vivax
malaria and uncomplicated P. falciparum malaria (MD:
-24.5, 95% CI: -57.8–8.6, P = 0.15). However, one study on
severe malaria [46] showed a relatively lower mean plate-
let count in patients with severe P. falciparum malaria
than in those with severe P. vivax malaria (MD: 46.0, 95%
CI: 37.5–54.5, P < 0.0001). This implied that the platelet
counts could vary with severity of malaria.
A pooled analysis of another 4 studies [12, 32, 59,
63] showed that 15% (95% CI: 9–21%) of P. vivax
malaria patients with thrombocytopaenia developed
Fig. 2 Proportion of severe to very severe thrombocytopaenia in patients with vivax malaria. TCP: Thrombocytopenia; ES: Effect estimate. The grey
zone indicates a very narrow 95% upper and lower bound. The size of these grey areas reflects the weightage of their contribution to the pooled
analysis. P value is not indicated by default, when I2 value becomes 0%
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minor bleeding episodes (Additional file 7). These
bleeding manifestations were epistaxis, haematemesis,
petechiae and purpura. A pooled analysis of 2 studies
[12, 37] showed a similar risk of developing bleeding
episodes for both thrombocytopaenia with severe P.
vivax malaria (15.7%, 70/445) and with P. falciparum
malaria (11.2%, 30/269) (OR: 0.67, 95% CI: 0.43–1.06,
P = 0.09). This implied that both P. vivax and P.
falciparum infections could present with bleeding
episodes should there be a change in platelet counts
in the infected patients.
Associated risks of thrombocytopaenia in P. vivax malaria
Three studies with PCR confirmed P. vivax malaria re-
ported parasite density. Of these, one study showed a
higher parasite density among patients with severe
thrombocytopaenia in P. vivax malaria than in those with
either mild thrombocytopaenia or no thrombocytopaenia
(P = 0.524) [26]. The remaining 2 studies [21, 38] qualita-
tively reported almost the same P. vivax parasite density in
patients with thrombocytopaenia and those without
thrombocytopaenia. This was indirectly supported by
another study with 456 non-PCR confirmed P. vivax,
showing no statistically significant relationship between
parasite density and thrombocytopaenia (R2 = 0). This
implied that parasite load was not a predictor of change in
platelet counts in these patients [39].
One study showed a significantly lower haemoglobin
(Hb) level with severe thrombocytopaenia (11.66 ± 2.19,
n = 79) compared to those with moderate thrombo-
cytopaenia (12.65 ± 1.63, n = 93) (P = 0.002) or the
healthy (non-malaria) participants (12.29 ± 1.99, n = 100)
(P = 0.05) [58]. This indicated that as the platelet count
decreased, so did the Hb level in patients with P. vivax
malaria. However, a small study reported that there was
no significant difference in Hb levels between P. vivax
malaria with severe thrombocytopaenia (n = 10) and those
with mild thrombocytopaenia (n = 45) (13.00 ± 3.25 vs
12.90 ± 3.25) (P = 0.9) or no thrombocytopaenia (normal
platelet counts) (n = 35) (13.00 ± 3.25 vs 12.10 ± 3.25)
(P = 0.4) [26]. The same study on patients with P. vivax
malaria reported that there were higher urea levels in pa-
tients with severe thrombocytopaenia (n = 10) compared
to patients with mild thrombocytopaenia (n = 45) (41.50 ±
10.37 vs 30.00 ± 7.20) (P < 0.001) or no thrombocytopaenia
(n = 35) (41.50 ± 10.37 vs 28.00 ± 7.00) (P < 0.001) [26].
Also, there was higher serum bilirubin levels in patients
Table 1 Distribution of thrombocytopaenia between vivax malaria and falciparum malaria
Study [Reference] thrombocytopaenia
grade
Vivax malaria Falciparum malaria Odds
ratio
95% CI
event total event total
Taylor, 2008 [69] severe 8 64 5 98 2.65 0.83–8.52
Poespoprodjo, 2009 [55] severe 23 88 5 51 3.25 1.15–9.19
Khan, 2012 [33] severe 5 39 22 82 0.4 0.14–1.15
Dhungat, 2013 [22] severe 19 54 13 28 0.62 0.24–1.58
Barber, 2013 [20] severe 19 43 61 122 0.79 0.39–1.59
Singh, 2014 [66] severe 32 90 32 90 1 0.54–1.84
Haroon, 2013 [30] severe 70 110 2 472 411.2 97.2–1739.5
Lampah, 2015 [11] severe 1650 19 552 5722 36 759 0.49 0.47–0.52
Tanwar, 2012 [12] very severe 60 278 13 145 2.79 1.47–5.28
Kochar, 2010b [38] very severe 26 460 9 525 3.43 1.59–7.4
Uttra, 2010 [70] very severe 18 85 11 78 1.64 0.72–3.72
Pooled, Odds Ratio I2 = 94.1% 1.98 0.92– 4.25
Fig. 3 Comparison of thrombocytopaenia in patients with vivax malaria
and with falciparum malaria. OR (95% CI): odds ratio and corresponding
95% confidence interval. The middle vertical line is OR 1, indicating a null
value. The horizontal line indicates study specific odds ratio and
corresponding 95% confidence interval. P value is not indicated by
default, when I2 value becomes 0%. Very severe TCP denotes very severe
thrombocytopenia; severe TCP denotes severe thrombocytopenia
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with severe thrombocytopaenia (n = 10) (1.70 ± 0.42) com-
pared to those with mild thrombocytopaenia (n = 45)
(1.30 ± 0.32) (P = 0.001) or no thrombocytopaenia (n = 35)
(0.90 ± 0.25) (P < 0.001) [26]. Therefore, a decreasing
platelet count was related to both elevated urea and serum
bilirubin levels in P. vivax infection. A study on 51
children in India had reported that the association of
severe P. vivax malaria in children with severe
thrombocytopaenia was 2.6 times significantly greater
than those with non-severe thrombocytopaenia (OR: 2.60,
95% CI: 1.20–5.52, P ≤ 0.014) [12].
One study has reported that anaemia with
thrombocytopaenia was more common in patients with
P. falciparum malaria (17.6%, 13/74 vs 39/103)
compared to those with P. vivax malaria (37.9%, 39/103)
(P = 0.004) [40].
Mortality risk
A pooled analysis of 2 studies with PCR confirmed para-
site species [40, 64] showed an equal risk of mortality
with severe thrombocytopaenia in P. vivax malaria pa-
tients (10.2%, 5/49) and P. falciparum malaria patients
(14%,8/57) (OR: 1.16, 95% CI: 0.30–4.60, P = 0.87)
(Additional file 8). Another study reported a 9-fold in-
crease in the risk of death from P. vivax malaria in chil-
dren with severe anaemia and severe thrombocytopaenia,
compared to those without anaemia or thrombocyto-
paenia (OR: 9.21, 95% CI: 4.53–18.73) [11].
Discussion
Based on available data from 58 individual observational
studies across 12 endemic countries, the current study
has provided some evidence of the increasing risks of
developing thrombocytopaenia in P. vivax malaria pa-
tients. The observational design in these studies was ap-
propriate as it quantified the frequency and associated
risks in regular clinical practice, reflecting real life situa-
tions. The findings suggest that thrombocytopaenia is a
common manifestation equally observed in both human
P. vivax and P. falciparum infections. A review of stud-
ies restricted to Brazil reported that the mortality rate in
P. vivax malaria with severe thrombocytopaenia alone
was comparable to that of P. falciparum malaria [4].
Our findings also suggest that both the magnitude of se-
vere thrombocytopaenia and mortality risks are similar
in both P. falciparum and P. vivax malaria. Dating back
to the era of induced malaria therapy, the fatality rate
with the Madagascar strain of P. vivax was 10–15%
when used to treat patients with neurosyphilis in the
United Kingdom [90]. Details of this evidence are
available elsewhere [80].
Although the mechanism of thrombocytopaenia in
malaria is not fully understood, numerous studies have
hypothesied possible patho-immunological mechanisms
of thrombocytopaenia in malaria. Oxidative stress [23],
macrophage colony stimulating factor [91], immuno-
globulin G binding to platelet-bound malaria antigens
[73], spleen pooling [92], increased plasma cell free cir-
culating nucleic acids levels in P. vivax [93] and platelet
phagocytosis [21] are possible mechanisms resulting in
damage to thrombocytes or the excessive removal of
platelets. A case study in India reported haemophagocy-
tosis occurring in a P. vivax malaria patient with a plate-
let count 16 000/mm3 [87]. Moreover, an interaction
between Plasmodium and platelets has been postulated
as P. vivax has been seen within the platelets of patients
when using electron microscopy [94]. It is probable that
thrombocytopaenia in malaria is actually a multifactorial
phenomenon [21].
In our review, we found that 10.1% of P. vivax infected
patients had severe to very severe thrombocytopaenia,
regardless of confirmatory tests used for P. vivax mal-
aria. Of note, a large-scale study in Indonesia [11] had
contributed to this pooled proportion, and there the
prevalence was 8.4% (1650/19 552). An earlier review re-
ported that the pooled proportion of severe thrombo-
cytopaenia was 7.5% (95% CI: 4.2–10.8%) amongst
outpatients with P. vivax malaria [95]. This difference
might be due to the periods covered by the included
studies, variation in selection criteria used by the reviews
and/or levels of malaria endemicity in the study areas.
Moreover, the proportion of thrombocytopaenia will be
higher in studies performed at tertiary-referral hospitals
(with a higher proportion of patients with severe vivax
malaria), and lower in community-based studies. In our
analysis, we included published studies between 1988
and 2015. We did not include studies with imported
malaria cases [72, 79, 89] nor those with pregnant
women included [76, 78]. The difference in the propor-
tion of severe thrombocytopaenia between the current
review and earlier review might also be due to the drug
resistance status of parasites in the study areas in the
included studies. It has been found that drug resistant
parasites prolong their stay in their hosts and do more
damage, resulting in thrombocytopaenia [96].
Clinical relevance
A limited number of studies included in this review doc-
umented that low Hb, and high serum bilirubin and urea
levels in P. vivax malaria were associated with severe
thrombocytopaenia. These findings implied that severe
anaemia, and impaired liver and renal functions would
be expected in patients with severe thrombocytopaenia
and P. vivax malaria. This also indicates that MOD may
occur in malaria patients with thrombocytopaenia. This
is a similar phenomenon to that seen in P. falciparum
infections. This provides further evidence to refute the
long-held view that P. vivax infection is benign [5, 11,
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38, 39, 80]. This misconception and may have led to in-
appropriate clinical management, research and control
[63] of P. vivax malaria. This collective evidence sup-
ports the need for increased efforts to actively control
and then eliminate both P. vivax [38] and P. falciparum
infections.
This review reported minor bleeding episodes.
Thrombocytopaenia, even in severe cases, was not com-
monly accompanied with severe bleeding [11, 24] or
clinical bleeding in malaria [12]. This might be due to
the good tolerance of a low platelet count in malaria pa-
tients through an enhanced aggregability pathway [49].
Another possibility is that larger platelets observed in
thrombocytopaenic patients may compensate for the low
number of platelets in the periphery, thereby preserving
primary haemostasis and avoiding severe bleeding [24].
The high proportion of severe thrombocytopaenia in P.
vivax malaria patients found in this review highlights
the clinical relevance of this parameter in diagnosis and
treatment. However, in the absence of (severe) bleeding
manifestations in malaria patients, thrombocytopaenia
alone is not regarded as a WHO criterion used to define
severe malaria [8]. Additionally, other severe manifesta-
tions in the form of impaired renal and liver function,
leading to MOD and increased mortality have been doc-
umented in studies from India [39] and Brazil [11] and
further highlight the need for a broadened clinical
awareness of P. vivax malaria and its complications.
Although it was not included in the current analysis, a
case study in India had reported retinal haemorrhage in
a patient of P. vivax malaria who had a platelet count of
40 000/mm3 [86].
Study limitations
The present study has several limitations. Not all studies
included in this review used the same methods for plate-
let ‘labelling’. Hence, misclassification bias could poten-
tially affect the interpretation of the results. For
instance, the haemolysis necessary to count platelets in
the chamber creates pseudo-platelets [97], resulting in
erroneously high numbers of platelets being counted.
This shortfall is avoided if an electronic counter is used
in which platelets are counted in platelet rich, red blood
cell free, and parasite-free plasma [72]. Moreover, semi-
immune malaria patients were likely to have low parasite
counts and may not have an increase in platelet count
even after treatment [72].
We did not undertake segregated analysis of thrombo-
cytopaenia by use or not of PCR confirmed speciation.
This is because microscopy by technicians at the malaria
clinics in the endemic countries may contribute to the
relatively minor possible errors. Moreover, PCR in the
studies included in the current review might have
excluded errors made by microscopists in the same
studies. Although the quality of the studies included was
variable if P. vivax malaria was not confirmed by PCR, the
current review attempted to minimize this problem by in-
cluding studies which focused on specific groups in en-
demic areas where P. vivax is prevalent. This reinforces our
confidence in the effect estimates. Nevertheless, the current
work focused exclusively on thrombocytopaenia and also
reported comparisons between P. vivax and P. falciparum
malaria other than solely giving frequencies of each disease
thereby yielding more reliable and comprehensive
information.
We were unable to rule out association of co-infections
such as intestinal parasitic infections [58], acute parvo-
virus B19 infection [98] or an endemic viral infection such
as dengue in Brazil [4]. These comorbid infections in pa-
tients included in the primary studies could contribute to
a substantial percentage of thrombocytopaenia [4]. One
published study highlighted that acute or chronic co-
morbidities were detected in 58% (14/24) of the patients
with P. vivax in the Western Brazilian Amazon [99].
Another confounding factor may occur if patients in the
primary studies had taken primaquine-containing antimal-
arial treatment, as they might have recovered normal
platelets counts. Hence, the interpretation of the current
findings needs to consider potential effects of co-infec-
tions and antimalarial medication as confounding factors.
The manifestations of thrombocytopaenia could also
be influenced by context-dependent factors such as the
level of malaria endemicity, accessibility to effective mal-
aria treatment and the age-specific and gender-specific
host immunity. We have found that a variation in the
risk of developing thrombocytopaenia in P. vivax malaria
between children and adults might be due to a difference
in immune status between the age groups. For instance,
young children exhibit an “antidisease immunity” that
affects the risk and extent of morbidity associated with a
given parasite density [100]. Inadequate data in the in-
cluded studies preclude the ability to perform stratified
analyses based on any of these potential influencing
factors.
Implications
Although further substantiation is required, one study
reported that patients with mild thrombocytopaenia
were about 32 times more likely to have malaria infec-
tion than those with normal platelet count (OR: 31.8,
95% CI: 25.1–39.7, P ≤ 0.001) [41]. An estimation of
platelet counts is readily available with an automated
blood counter even in some remote health posts, where
other biochemical and inflammatory markers are not
available. The presence of thrombocytopaenia in people
from malaria endemic areas may also be useful to sup-
port the diagnosis of malaria in cases with low levels of
parasite biomass [41], as it is common in natural P.
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vivax infections. Since severe thrombocytopaenia may
be associated with several infectious diseases such as
dengue and leptospirosis, patients with persistent
thrombocytopaenia in malaria endemic areas should also
be thoroughly investigated for co-infections or other
identifiable causes of thrombocytopaenia.
The association of severe malaria was found to be stron-
ger with severe thrombocytopaenia in children with a spe-
cificity of 88.3% and a positive predictive value of 85%
[12]. Therefore, the presence of severe thrombocytopaenia
should serve as a warning sign of poor outcome, particu-
larly when coexisting with severe anaemia [11]. Any pa-
tient with an acute febrile illness without localized signs
and having a combination of anaemia and thrombocyto-
paenia should raise the possibility of malaria infection,
and they should then proceed to use confirmatory tests
[12]. The increased mortality risk in vivax malaria cases
with severe thrombocytopaenia as well as severe anaemia
highlights the need for healthcare personnel to promptly
examine for these signs in malaria patients living in
endemic areas.
Based on the findings, patients with severe thrombo-
cytopaenia in malaria endemic settings and without other
definitive causes for the thrombocytopaenia should be
treated as severe malaria [12] and the presence of severe
thrombocytopaenia should be included as a defining cri-
terion of malaria severity for both P. falciparum and P.
vivax malaria [11]. The platelet count (indicating the
presence of thrombocytopaenia) coupled with other
clinical and microscopy parameters can significantly
improve malaria diagnosis, provide timely treatment
for malaria infections [41] and address the associated
higher morbidity and mortality risks.
Conclusion
The current review has provided some evidence of the
clinical relevance of severe thrombocytopaenia in P. vivax
malaria. To substantiate these findings, there is a need for
future well designed, large-scale, prospective studies
among patients infected with P. vivax from different
countries and epidemiological settings with various age
and gender groups represented.
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